Faster Pipeline Progression Discussed By Catalent Expert EAC 2012




Faster Pipeline Progression is Discussed by Catalent Expert at European Antibody Congress 2012

Somerset, NJ, November 26, 2012 – Greg Bleck, Ph.D., R&D Platform Director-Biologics, Catalent Pharma Solutions, will participate in a panel discussion titled “How collaboration can lead to faster pipeline progression,” on Wednesday, November 28, 2012 at the European Antibody Congress 2012 at the Starling Geneva Hotel & Conference Center, Geneva, Switzerland.

Part of the event’s Monoclonal Antibody Track, the panel discussion will follow the presentation of a partnership case study on Pritumumab by Mark Glassy, Chief Executive Officer of Nascent Biologics, Inc., and will examine how the collaboration was established and the skill set brought by each company. The session will go on to discuss the benefits of developing pipelines in this manner, factoring on timescales, cost and scientific expertise. It will conclude by looking to the future and how such relationships can help to take more products through the clinic to the market.
 
Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics. He has a broad background in molecular biology, mammalian gene expression, cell culture and transgenic animals. Dr. Bleck holds a Bachelor’s degree in Dairy Science and has a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison.  He performed postdoctoral work at the University of Illinois-Urbana, working in the areas of gene regulation and expression. Dr. Bleck has published more than 55 research papers and co-authored three book chapters.
 
For further information and to register, please visit http://www.terrapinn.com/2012/european-antibody-congress .

To schedule an interview with Dr. Bleck, please contact Chris Halling at Chris.Halling@catalent.com .

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.

more products. better treatments. reliably supplied.™